Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
RESEARCH TOOLSreports
KPTI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.53 - $1.70
Previous CloseN/A
Volume220.82K
Average Volume (3M)796.09K
Market Cap
$79.50M
Enterprise Value$164.46M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.34
Next Earnings
May 01, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.14
Shares Outstanding126,190,740
10 Day Avg. Volume1,009,370
30 Day Avg. Volume796,086
Standard Deviation0.19
R-Squared0.00024
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.53
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.17
Enterprise Value/Ebitda-3.02
Forecast
1Y Price Target
$5.00Price Target Upside733.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Karyopharm Therapeutics News
PremiumCompany Announcements
Karyopharm’s Earnings Call: Growth Amid Financial Challenges
PremiumCompany Announcements
Karyopharm’s 2024 Earnings and Clinical Progress---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsXpovio has FDA Fast Track Designation for the treatment of patients with myelofibrosis (MF).
Market PotentialKaryopharm estimates a peak revenue opportunity of $1 billion for Xpovio in MF.
Regulatory ApprovalKaryopharm announced reimbursement decisions in France and Italy, and approvals for Xpovio in Turkey, South Korea, Thailand, and Malaysia.
Bears Say
Competitive PressureAnalysts remain on the sidelines pending more durable commercial growth trends for Xpovio in multiple myeloma, convincing evidence that Xpovio sales growth will not be overshadowed by existing operating expenses, and a clearer picture on the potential opportunities for the drug beyond multiple myeloma.
Sales PerformanceXpovio sales were up quarter-over-quarter but down year-over-year, indicating some challenges in maintaining consistent growth.
Trial DelaysTop-line endometrial Phase 3 data delayed to early 2026 on higher screen-failure rate.
---
Ownership Overview
2.44% Insiders
9.29% Mutual Funds
20.38% Other Institutional Investors
60.19% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KPTI FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
Karyopharm Therapeutics lowest stock price was $0.53 and its highest was $1.70 in the past 12 months.
What is Karyopharm Therapeutics’s market cap?
Karyopharm Therapeutics’s market cap is $79.50M.
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s upcoming earnings report date is May 01, 2025 which is in 69 days.
How were Karyopharm Therapeutics’s earnings last quarter?
Karyopharm Therapeutics released its earnings results on Feb 19, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.261 by $0.021.
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate is -0.27.
How many shares outstanding does Karyopharm Therapeutics have?
Karyopharm Therapeutics has 126,190,740 shares outstanding.
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Karyopharm Therapeutics reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.261. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Currently, no hedge funds are holding shares in KPTI
---
Karyopharm Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.00 (733.33% Upside)
$5.00 (733.33% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 8.8%
Last 30 Days ▲ 8.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.75%
12-Months-Change
Fundamentals
Return on Equity
54.80%
Trailing 12-Months
Asset Growth
-29.81%
Trailing 12-Months
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
---
KPTI Company Deck
---
KPTI Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong growth in XPOVIO net product revenue and significant progress in clinical trials for myelofibrosis and endometrial cancer. However, challenges included a decrease in total revenue from licensing agreements, an increased gross-to-net discount, and a reduced cash position, signaling potential financial concerns. The overall sentiment is balanced with notable achievements offset by financial challenges.Read More>---
KPTI Stock 12 Month Forecast
Average Price Target
$5.00
▲(733.33% Upside)
Technical Analysis
Neurocrine
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Bluebird Bio
―
Blueprint Medicines
―
Best Analysts Covering KPTI
1 Year
1 Year Success Rate
2/28 ratings generated profit
1 Year Average Return
-45.48%
reiterated a buy rating 3 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 7.14% of your transactions generating a profit, with an average return of -45.48% per trade.
---